MedPath

Biologics by McKesson Selected as Exclusive Pharmacy for Progeria Drug ZOKINVY

  • Biologics by McKesson has been chosen by Sentynl Therapeutics as the exclusive specialty pharmacy for ZOKINVY in the U.S.
  • ZOKINVY (lonafarnib) is the only FDA-approved treatment option for Hutchinson-Gilford Progeria Syndrome and certain Progeroid Laminopathies.
  • This ultra-rare genetic disease affects approximately one in 18-20 million people in the United States, causing premature aging and mortality in children.
  • Biologics by McKesson will ensure that patients prescribed ZOKINVY receive the necessary support and management to optimize their treatment.
CARY, N.C. – Biologics by McKesson has been selected by Sentynl Therapeutics as the exclusive specialty pharmacy for ZOKINVY® (lonafarnib) in the United States. This appointment aims to streamline access and support for patients with Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies, who rely on this critical medication.
ZOKINVY, a farnesyltransferase inhibitor, is approved by the FDA for patients aged 12 months and older with a body surface area of 0.39 m2 and above. Its indications include reducing the risk of mortality in Hutchinson-Gilford Progeria Syndrome and treating processing-deficient Progeroid Laminopathies with specific genetic mutations. These mutations include Heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations.
Hutchinson-Gilford Progeria Syndrome is an ultra-rare genetic condition characterized by accelerated aging in children. The estimated prevalence in the United States is approximately one in 18 to 20 million people. The exclusive partnership between Sentynl and Biologics by McKesson is designed to ensure that patients prescribed ZOKINVY receive prompt intervention and comprehensive management to optimize treatment outcomes.
"ZOKINVY is the first and only treatment option for Progeria," said Ela Lourido, vice president and general manager, Specialty Pharmacy Solutions, McKesson. "This is a groundbreaking milestone, and Biologics is honored to be chosen as the specialty pharmacy provider by Sentynl to offer this important medication to patients who need it."
Biologics by McKesson emphasizes a patient-centric approach, providing specialized support through pharmacists with expertise in rare diseases, experienced nurses, and financial counselors. This multidisciplinary team assists patients in navigating financial assistance programs and accessing resources to support their treatment journey.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Rejects Lexicon's Zynquista for Type 1 Diabetes and Chronic Kidney Disease

The FDA issued a Complete Response Letter for Lexicon's Zynquista (sotagliflozin) for type 1 diabetes and chronic kidney disease, marking its second rejection.

FDA Approves Cobenfy, a Novel Muscarinic Receptor-Targeting Drug for Schizophrenia

The FDA has approved Cobenfy (xanomeline-trospium), the first new mechanism of action in schizophrenia treatment in over 70 years, targeting muscarinic cholinergic receptors.

FDA Grants Breakthrough Therapy Designation to Nipocalimab for Sjögren's Disease

Johnson & Johnson's nipocalimab received Breakthrough Therapy Designation from the FDA for treating moderate-to-severe Sjögren's disease, an autoimmune disorder.

Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease

The FDA granted Breakthrough Therapy Designation to nipocalimab for treating moderate-to-severe Sjögren’s disease in adults, addressing a critical unmet need.

FDA Authorizes Phase 2a Trial of Progerinin for Hutchinson-Gilford Progeria Syndrome

The FDA has authorized a Phase 2a clinical trial for Progerinin, a novel drug developed by PRG Science & Technology for Progeria treatment.

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis

The U.S. FDA has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, marking it as the first IL-23 antagonist approved for both ulcerative colitis and Crohn's disease. This approval is based on two Phase 3 clinical trials, INSPIRE and COMMAND, which demonstrated the drug's efficacy in achieving clinical remission and endoscopic improvement.

Spinogenix Receives FDA Orphan Drug Designation for SPG601 to Treat Fragile X Syndrome

Spinogenix, Inc. has been granted Orphan Drug Designation by the U.S. FDA for SPG601, a novel treatment for Fragile X syndrome (FXS), highlighting the urgent need for new therapies. FXS, a leading cause of inherited intellectual disability and autism, lacks FDA-approved treatments. SPG601 aims to address core symptoms by modulating BK channels to restore synaptic function.

Two Major Breakthroughs in Fragile X Syndrome Treatments

Recent advancements in Fragile X Syndrome (FXS) treatments include Spinogenix's FDA approval for a Phase II clinical trial of SPG601 and the European Commission granting orphan drug status to Shionogi’s zatolmilast. These developments aim to address the significant unmet need for effective treatments in FXS, a condition causing developmental problems and cognitive impairment.

FDA Grants Breakthrough Therapy Designation to Latozinemab for FTD-GRN

The FDA has granted Breakthrough Therapy Designation to latozinemab for frontotemporal dementia with a progranulin gene mutation (FTD-GRN).

FDA Grants Priority Review to Dizal's Sunvozertinib for EGFR Exon20 Insertion-Positive NSCLC

The FDA has granted priority review to sunvozertinib for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy.

Reference News

[1]
ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria ...
mckesson.com · Sep 10, 2024

Biologics by McKesson selected as exclusive specialty pharmacy for ZOKINVY® (lonafarnib) by Sentynl Therapeutics, Inc. Z...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy